Siponimod Patent Expiration

1. Mayzent patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist
Nov, 2030

(6 years from now)

US11944602 NOVARTIS Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 26, 2024
M(M-274) Mar 01, 2025

NCE-1 date: 27 March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically ...

Dosage: TABLET

How can I launch a generic of MAYZENT before it's drug patent expiration?
More Information on Dosage

MAYZENT family patents

Family Patents